En esta web podrás encontrar toda la información relativa a las publicaciones en ASCO 2022 de Ribociclib, así como contenido relacionado de interés de la molécula y un link a la agenda del congreso.
Poster OS ML2 – Dose reductionRibociclib (Abstract # 1017)Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA (ML)-2 |
|
|
Para poder descargar estos materiales debes estar registrado en Médicamente. Si todavía no eres usuario, únete aquí.
Oral Abstract SessionRibociclib (Abstract LBA1004) A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial
|
Poster SessionRibociclib (Abstract # 1065) Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA
|
Poster DiscussionRibociclib (Abstract # 1015) Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)
|